版本:
中国

BRIEF-Minerva provides update on phase 3 design and development strategy for MIN-101

May 15 Minerva Neurosciences Inc

* Minerva provides update on phase 3 design and development strategy for MIN-101

* Minerva Neurosciences Inc - in phase 4 development, company plans to conduct additional trials to expand profile of MIN-101

* Minerva Neurosciences Inc -co's next step is planned initiation of a pivotal phase 3 trial with MIN-101 in second half of 2017

* Minerva Neurosciences - plans for its phase 3 and phase 4 clinical development of MIN-101, a drug targeting negative symptoms in schizophrenia patients

* Minerva Neurosciences Inc says may conduct a trial in adolescents at high risk for schizophrenia who during prodromal phase manifest negative symptoms

* Minerva Neurosciences- plans to assess indications as expansion options for MIN-101 in development program beyond planned phase 3 study in schizophrenia Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐